HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome
Antioxidants · 03.04.2025 · 14 (4) · 434
DOI: 10.3390/antiox14040434 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 03.04.2025. Verfasst von Sebastià Alcover und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute Sant Pau (IR SANT PAU), 08041 Barcelona, Spain. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR, EU Horizon 2020.
Abstract (Originalsprache)
Metabolic syndrome (MetS) is a complex cluster of interrelated metabolic disorders that significantly elevate the risk of cardiovascular disease, making it a pressing public health concern worldwide. Among the key features of MetS, dyslipidemia—characterized by altered levels of high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)—plays a crucial role in the disorder’s progression. This review aims to elucidate the intricate interplay between HDL-C and TG within the context of lipid metabolism and cardiovascular health, while also addressing the detrimental impact of various cardiovascular risk factors and associated comorbidities. The dynamics of HDL-C and TG are explored, highlighting their reciprocal relationship and respective contributions to the pathophysiology of MetS. Elevated levels of TGs are consistently associated with reduced concentrations of HDL-C, resulting in a lipid profile that promotes the development of vascular disease. Specifically, as TG levels rise, the protective cardiovascular effects of HDL-C are diminished, leading to the increased accumulation of pro-atherogenic TG-rich lipoproteins and low-density lipoprotein particles within the vascular wall, contributing to the progression of atheromas, which can ultimately result in significant ischemic cardiovascular events. Ultimately, this paper underscores the significance of HDL and TG as essential targets for therapeutic intervention, emphasizing their potential in effectively managing MetS and reducing cardiovascular risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Institute Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.
- Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain.
- Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Instituto de Salud Carlos III, 28029 Madrid, Spain.
ORCID-Profile: Sebastià Alcover, Lisaidy Ramos-Regalado, Natàlia Muñoz-García
Förderung
- Agencia Estatal de Investigación
- Unión Europea NextGenerationEU/PRTR
- EU Horizon 2020
- Fondo Europeo de Desarrollo Regional (FEDER)
- Generalitat of Catalunya-Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat
- Agencia Gestión Ayudas Universitarias Investigación: AGAUR
- Generalitat of Catalunya-Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat
Zitieren
APA
Alcover, S., Ramos-Regalado, L., Girón, G., Muñoz-García, N., & Vilahur, G. (2025). HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome. Antioxidants, 14(4), 434. https://doi.org/10.3390/antiox14040434
Vancouver
Alcover S, Ramos-Regalado L, Girón G, Muñoz-García N, Vilahur G. HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome. Antioxidants. 2025;14(4):434. doi:10.3390/antiox14040434
BibTeX
@article{Alcover2025,
author = {Alcover, Sebastià and Ramos-Regalado, Lisaidy and Girón, Gabriela and Muñoz-García, Natàlia and Vilahur, Gemma},
title = {HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {4},
pages = {434},
doi = {10.3390/antiox14040434}
}
EUVIMED